Tag: $Johnson & johnson

Johnson & Johnson (JNJ.N), said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, expanding the medtech conglomerate’s presence in solid tumors and prostate cancer treatments.

Johnson & Johnson raised its full-year sales forecast on Wednesday after beating estimates for second-quarter profit on strong demand for its cancer drug, Darzalex, and strength in its medical device business.

The U.S. Food and Drug Administration has approved Johnson & Johnson’s (JNJ.N),  drug to treat some patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.

J&J beat quarterly profit and revenue expectations and raised its dividend but didn’t change its profit outlook, and the stock pulled back.

A U.S. bankruptcy judge on Monday rejected Johnson & Johnson’s (JNJ.N), opens new tab $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company’s bankruptcy strategy has failed in court.

Johnson & Johnson  plans to spend over $55 billion to build four plants in the U.S., it said on Friday, as a threat of drug import duties from the Trump administration forces companies to expand their manufacturing operations domestically.

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby powder caused ovarian cancer, as it tries to convince a judge to sign off on its third attempt to resolve thousands of lawsuits through a subsidiary’s bankruptcy.

Johnson & Johnson’s stock reversed gains made early Wednesday immediately after earnings were released, after the medical technology and drug company beat estimates for the fourth quarter, but offered some mixed guidance.

Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and quarterly results that beat Wall Street expectations.

Johnson & Johnson stock was slipping Wednesday after the pharmaceutical company beat expectations for its second-quarter earnings.

Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other talc-based products blamed for allegedly causing cancer.

Johnson & Johnson reported first-quarter adjusted earnings that topped expectations as sales in its medical devices business surged.

Johnson & Johnson  agreed to acquire medical-devices maker Shockwave Medical  for a total enterprise value of about $13.1 billion.

Johnson & Johnson reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations.

Johnson & Johnson said on Monday it had agreed to buy drug developer Ambrx Biopharma  for $2 billion to gain access to drugs that belong to a class of targeted cancer therapies which have drawn interest from other drugmakers.

Johnson & Johnson stock was edging higher after the pharmaceutical and medical-device company shared its long-term financial outlook.

Johnson & Johnson topped quarterly earnings and revenue estimates.

Johnson & Johnson on Wednesday forecast 12.5% growth in its annual adjusted profit after completing the separation of consumer health company Kenvue .

Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations due to strong sales growth from the company’s medtech business.